Targeting cellular apoptotic pathway with peptides from marine organisms

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 1, 2013, Pages 42-48

  Zheng, Lanhong ^a   Lin, Xiukun ^b   Wu, Ning ^c   Liu, Ming ^c   Zheng, Yuan ^a   Sheng, Jun ^a   Ji, Xiaofeng ^a   Sun, Mi ^a  

^a YELLOW SEA FISHERIES RESEARCH INSTITUTE   (China)

^b Beijing City University   (China)

^c INSTITUTE OF OCEANOLOGY   (China)

Author keywords

Apoptosis; Marine organisms; Peptides

Indexed keywords

ANTINEOPLASTIC AGENT; ARENAMIDE A; ARENAMIDE B; BRENTUXIMAB VEDOTIN; C PHYCOCYANIN; CASPASE 8; CASPASE 9; CYTOCHROME C; DEHYDRODIDEMNIN B; DIDEMNIN B; DOLASTATIN 10; DOLASTATIN 15; ELISIDEPSIN; FW 523 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JASPAMIDE; KAHALALIDE F; MITOGEN ACTIVATED PROTEIN KINASE P38; NATURAL PRODUCT; PARDAXIN; PEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPEPTIDE CS 5931; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SANSALVAMIDE A; SOMOCYSTINAMIDE A; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CELL CULTURE; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MARINE SPECIES; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AQUATIC ORGANISMS; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS;

EID: 84876375516     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.02.006     Document Type: Review

References (94)

1. Reed J.C. Mechanisms of apoptosis. Am. J. Pathol. 2000, 157:1415-1430.
2. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
3. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462.
4. Rowinsky E.K. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J. Clin. Oncol. 2005, 23:9394-9407.
5. Call J.A., Eckhardt S.G., Camidge D.R. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol. 2008, 9:1002-1011.
6. Iannolo G., Conticello C., Memeo L., De Maria R. Apoptosis in normal and cancer stem cells. Crit. Rev. Oncol. Hematol. 2008, 66:42-51.
7. Burz C., Berindan-Neagoe I., Balacescu O., Irimie A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol. 2009, 48:811-821.
8. Fulda S., Pervaiz S. Apoptosis signaling in cancer stem cells. Int. J. Biochem. Cell Biol. 2009, 42:31-38.
9. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 2005, 55:178-194.
10. Eberle J., Fecker L.F., Forschner T., Ulrich C., Röwert-Huber J., Stockfleth E. Apoptosis pathways as promising targets for skin cancer therapy. Br. J. Dermatol. 2007, 156:18-24.
11. Ziegler D.S., Kung A.L. Therapeutic targeting of apoptosis pathways in cancer. Curr. Opin. Oncol. 2008, 20:97-103.
12. Ledgerwood E.C., Morison I.M. Targeting the apoptosome for cancer therapy. Clin. Cancer Res. 2009, 15:420-424.
13. Lin X.K., Liu M., Hu C.X., Liao D.J. Targeting cellular proapoptotic molecules for developing anticancer agents from marine sources. Curr. Drug Targets 2010, 11:708-715.
14. von Schwarzenberg K., Vollmar A.M. Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy. Cancer Lett. 2010, 10.1016/j.canlet.2010.1007.1004.
15. Reed J.C. Mechanisms of apoptosis. Am. J. Pathol. 2000, 157:1415-1430.
16. Oliver L., Vallette F.M. The role of caspases in cell death and differentiation. Drug Resist. Updat. 2005, 8:163-170.
17. Abe K., Kurakin A., Mohseni-Maybodi M., Kay B., Khosravi-Far R. The complexity of TNF-related apoptosis-inducing ligand. Ann. N. Y. Acad. Sci. 2000, 926:52-63.
18. Ozoren N., El-Deiry W.S. Cell surface Death Receptor signaling in normal and cancer cells. Semin. Cancer Biol. 2003, 13:135-147.
19. Peter M.E., Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003, 10:26-35.
20. Thorburn A. Death receptor-induced cell killing. Cell. Signal. 2004, 16:139-144.
21. Kroemer G. Mitochondrial control of apoptosis: an introduction. Biochem. Biophys. Res. Commun. 2003, 304:433-435.
22. Gupta S., Kass G.E., Szegezdi E., Joseph B. The mitochondrial death pathway: a promising therapeutic target in diseases. J. Cell. Mol. Med. 2009, 13:1004-1033.
23. Suarez-Jimenez G.M., Burgos-Hernandez A., Ezquerra-Brauer J.M. Bioactive peptides and depsipeptides with anticancer potential: sources from marine animals. Mar. Drugs 2012, 10:963-986.
24. Zheng L.H., Wang Y.J., Sheng J., Wang F., Zheng Y., Lin X.K., Sun M. Antitumor peptides from marine organisms. Mar. Drugs 2011, 9:1840-1859.
25. Yip K.W., Reed J.C. Bcl-2 family proteins and cancer. Oncogene 2008, 27:6398-6406.
26. Okun I., Balakin K.V., Tkachenko S.E., Ivachtchenko A.V. Caspase activity modulators as anticancer agents. Anticancer Agents Med. Chem. 2008, 8:322-341.
27. Ghavami S., Hashemi M., Ande S.R., Yeganeh B., Xiao W., Eshraghi M., Bus C.J., Kadkhoda K., Wiechec E., Halayko A.J., Los M. Apoptosis and cancer: mutations within caspase genes. J. Med. Genet. 2009, 46:497-510.
28. Martelli A.M., Tazzari P.L., Evangelisti C., Chiarini F., Blalock W.L., Billi A.M., Manzoli L., McCubrey J.A., Cocco L. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr. Med. Chem. 2007, 14:2009-2023.
29. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15:1126-1132.
30. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15:1126-1132.
31. Wong W.W., Puthalakath H. Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway. IUBMB Life 2008, 60:390-397.
32. Braekman J.C., Daloze D., Moussiaux B., Riccio R. Jaspamide from the marine sponge Jaspis johnstoni. J. Nat. Prod. 1987, 50:994-995.
33. Odaka C., Sanders M.L., Crews P. Jasplakinolide induces apoptosis in various transformed cell lines by a caspase-3-like protease-dependent pathway. Clin. Diagn. Lab. Immunol. 2000, 7:947-952.
34. Cioca D.P., Kitano K. Induction of apoptosis and CD10/neutral endopeptidase expression by jaspamide in HL-60 line cells. Cell. Mol. Life Sci. 2002, 59:1377-1387.
35. Watts K.R., Morinaka B.I., Amagata T., Robinson S.J., Tenney K., Bray W.M., Gassner N.C., Lokey R.S., Media J., Valeriote F.A., Crews P. Biostructural features of additional jasplakinolide (jaspamide) analogues. J. Nat. Prod. 2011, 74:341-351.
36. Pettit G.R., Kamano Y., Fujii Y., Herald C.L., Inoue M., Brown P., Gust D., Kitahara K., Schmidt J.M., Doubek D.L., Michel C. Marine animal biosynthetic constituents for cancer chemotherapy. J. Nat. Prod. 1981, 44:482-485.
37. Luesch H., Moore R.E., Paul V.J., Mooberry S.L., Corbett T.H. Isolation of Dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue Symplostatin 1. J. Nat. Prod. 2001, 64:907-910.
38. Bai R., Pettit G.R., Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol. 1990, 39:1941-1949.
39. Maki A., Diwakaran H., Redman B., al-Asfar S., Pettit G.R., Mohammad R.M., al-Katib A. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs 1995, 6:392-397.
40. Thornburg C.C., Thimmaiah M., Shaala L.A., Hau A.M., Malmo J.M., Ishmael J.E., Youssef D.T., McPhail K.L. Cyclic depsipeptides, grassypeptolides D and E and Ibu-epidemethoxylyngbyastatin 3, from a Red Sea Leptolyngbya cyanobacterium. J. Nat. Prod. 2011, 74:1677-1685.
41. Francisco J.A., Cerveny C.G., Meyer D.L., Mixan B.J., Klussman K., Chace D.F., Rejniak S.X., Gordon K.A., DeBlanc R., Toki B.E., Law C.L., Doronina S.O., Siegall C.B., Senter P.D., Wahl A.F. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102:1458-1465.
42. Doronina S.O., Toki B.E., Torgov M.Y., Mendelsohn B.A., Cerveny C.G., Chace D.F., DeBlanc R.L., Gearing R.P., Bovee T.D., Siegall C.B., Francisco J.A., Wahl A.F., Meyer D.L., Senter P.D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21:778-784.
43. van de Donk N.W., Dhimolea E. Brentuximab vedotin. MAbs 2012, 4:458-465.
44. FDA approves brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. Oncology 2011, 25:904.
45. Minich S.S. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. Ann. Pharmacother. 2012, 46:377-383.
46. Oki Y., Younes A. Brentuximab vedotin in systemic T-cell lymphoma. Expert. Opin. Biol. Ther. 2012, 12:623-632.
47. Huang T.C., Lee J.F., Chen J.Y. Pardaxin, an antimicrobial peptide, triggers caspase-dependent and ROS-mediated apoptosis in HT-1080 cells. Mar. Drugs 2011, 9:1995-2009.
48. Nogle L.M., Gerwick W.H. Somocystinamide A, a novel cytotoxic disulfide dimer from a Fijian marine cyanobacterial mixed assemblage. Org. Lett. 2002, 4:1095-1098.
49. Wrasidlo W., Mielgo A., Torres V.A., Barbero S., Stoletov K., Suyama T.L., Klemke R.L., Gerwick W.H., Carson D.A., Stupack D.G. The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2313-2318.
50. Schirmer T., Huber R., Schneider M., Bode W., Miller M., Hackert M.L. Crystal structure analysis and refinement at 2.5A of hexameric C-phycocyanin from the cyanobacterium Agmenellum quadruplicatum. The molecular model and its implications for light-harvesting. J. Mol. Biol. 1986, 188:651-676.
51. Li B., Gao M.H., Zhang X.C., Chu X.M. Molecular immune mechanism of C-phycocyanin from Spirulina platensis induces apoptosis in HeLa cells in vitro. Biotechnol. Appl. Biochem. 2006, 43:155-164.
52. Scorrano L. Opening the doors to cytochrome c: changes in mitochondrial shape and apoptosis. Int. J. Biochem. Cell Biol. 2009, 41:1875-1883.
53. Cheng L.Y., Wang C.G., Liu H.Z., Wang F.X., Zheng L.H., Zhao J., Chu E., Lin X.K. A novel polypeptide extracted from Ciona savignyi induces apoptosis through a mitochondrial-mediated pathway in human colorectal carcinoma cells. Clin. Colorectal Cancer 2012, 11:207-214.
54. Wang C.C., Liu M., Cheng L.Y., Wei J.T., Wu N., Zheng L.H., Lin X.K. A novel polypeptide from Meretrix meretrix Linnaeus inhibits the growth of human lung adenocarcinoma. Exp. Biol. Med. 2012, 237:442-450.
55. Dhanasekaran D.N., Reddy E.P. JNK signaling in apoptosis. Oncogene 2008, 27:6245-6251.
56. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009, 9:537-549.
57. Depenbrock H., Peter R., Faircloth G.T., Manzanares I., Jimeno J., Hanauske A.R. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br. J. Cancer 1998, 78:739-744.
58. Urdiales J.L., Morata P., Nunez De Castro I., Sanchez-Jimenez F. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett. 1996, 102:31-37.
59. Garcia-Fernandez L.F., Losada A., Alcaide V., Alvarez A.M., Cuadrado A., Gonzalez L., Nakayama K., Nakayama K.I., Fernandez-Sousa J.M., Munoz A., Sanchez-Puelles J.M. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 2002, 21:7533-7544.
60. Rinehart K.L. Antitumor compounds from tunicates. Med. Res. Rev. 2000, 20:1-27.
61. Faivre S., Chieze S., Delbaldo C., Ady-Vago N., Guzman C., Lopez-Lazaro L., Lozahic S., Jimeno J., Pico F., Armand J.P., Martin J.A., Raymond E. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J. Clin. Oncol. 2005, 23:7871-7880.
62. Maroun J.A., Belanger K., Seymour L., Matthews S., Roach J., Dionne J., Soulieres D., Stewart D., Goel R., Charpentier D., Goss G., Tomiak E., Yau J., Jimeno J., Chiritescu G., National Cancer G. Phase I study of Aplidine in a daily×5 one-hour infusion every 3weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann. Oncol. 2006, 17:1371-1378. Institute of Canada Clinical Trials Group.
63. Nalda-Molina R., Valenzuela B., Ramon-Lopez A., Miguel-Lillo B., Soto-Matos A., Perez-Ruixo J.J. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. Cancer Chemother. Pharmacol. 2009, 64:97-108.
64. Xie J.J., Zhou F., Li E.M., Jiang H., Du Z.P., Lin R., Fang D.S., Xu L.Y. FW523-3, a novel lipopeptide compound, induces apoptosis in cancer cells. Mol. Med. Rep. 2011, 4:759-763.
65. Brugge J., Hung M.C., Mills G.B. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007, 12:104-107.
66. Yu L., Wang L.T., Chen S.W. Dual character of Toll-like receptor signaling: pro-tumorigenic effects and anti-tumor functions. Biochim. Biophys. Acta 2012, 1835:144-154.
67. Hamann M.T., Otto C.S., Scheuer P.J., Dunbar D.C. Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp. J. Org. Chem. 1996, 61:6594-6600.
68. Janmaat M.L., Rodriguez J.A., Jimeno J., Kruyt F.A., Giaccone G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol. Pharmacol. 2005, 68:502-510.
69. Ling Y.H., Aracil M., Zou Y., Yuan Z., Lu B., Jimeno J., Cuervo A.M., Perez-Soler R. PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase. Clin. Cancer Res. 2011, 17:5353-5366.
70. Ling Y.H., Aracil M., Jimeno J., Perez-Soler R., Zou Y. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur. J. Cancer 2009, 45:1855-1864.
71. Teixido C., Arguelaguet E., Pons B., Aracil M., Jimeno J., Somoza R., Mares R., Ramon Y.C.S., Hernandez-Losa J. ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines. Int. J. Oncol. 2012, 41:317-324.
72. Sato M., Sagawa M., Nakazato T., Ikeda Y., Kizaki M. A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells. Int. J. Oncol. 2007, 30:1453-1459.
73. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
74. Schneider G., Kramer O.H. NFkappaB/p53 crosstalk-a promising new therapeutic target. Biochim. Biophys. Acta 2011, 1815:90-103.
75. Yu Y.H., Wan Y., Huang C.S. The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target. Curr. Cancer Drug Targets 2009, 9:566-571.
76. Tas S.W., Vervoordeldonk M.J., Tak P.P. Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer. Curr. Gene Ther. 2009, 9:160-170.
77. Li F., Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta 2010, 1805:167-180.
78. Asolkar R.N., Freel K.C., Jensen P.R., Fenical W., Kondratyuk T.P., Park E.J., Pezzuto J.M. Arenamides A-C, cytotoxic NFkappaB inhibitors from the marine actinomycete Salinispora arenicola. J. Nat. Prod. 2009, 72:396-402.
79. Rinehart K.L., Gloer J.B., Hughes R.G., Renis H.E., McGovren J.P., Swynenberg E.B., Stringfellow D.A., Kuentzel S.L., Li L.H. Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 1981, 212:933-935.
80. Schmitz F., Bowden B., Toth S. Antitumor and cytotoxic compounds from marine organisms. Mar. Biotechnol. 1993, 1:197-308.
81. Blunden G. Biologically active compounds from marine organisms. Phytother. Res. 2001, 15:89-94.
82. Grubb D.R., Wolvetang E.J., Lawen A. Didemnin B induces cell death by apoptosis: the fastest induction of apoptosis ever described. Biochem. Biophys. Res. Commun. 1995, 215:1130-1136.
83. Johnson K.L., Lawen A. Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25. Immunol. Cell Biol. 1999, 77:242-248.
84. Vervoort H., Fenical W., Epifanio R.A. Tamandarins A and B: new cytotoxic depsipeptides from a Brazilian ascidian of the family Didemnidae. J. Org. Chem. 2000, 65:782-792.
85. Lee J., Currano J.N., Carroll P.J., Joullie M.M. Didemnins, tamandarins and related natural products. Nat. Prod. Rep. 2012, 29:404-424.
86. Chun H., Davies B., Hoth D., Suffness M., Plowman J., Flora K., Grieshaber C., Leyland-Jones B. Didemnin B. Invest. New Drug 1986, 4:279-284.
87. Rinehart K.L., Holt T.G., Fregeau N.L., Keifer P.A., Wilson G.R., Perun T.J., Sakai R., Thompson A.G., Stroh J.G., Shield L.S., Seigler D.S., Li L.H., Martin D.G., Grimmelikhuijzen C.J.P., Gäde G. Bioactive compounds from aquatic and terrestrial sources. J. Nat. Prod. 1990, 53:771-792.
88. Hwang Y., Rowley D., Rhodes D., Gertsch J., Fenical W., Bushman F. Mechanism of inhibition of a poxvirus topoisomerase by the marine natural product sansalvamide A. Mol. Pharmacol. 1999, 55:1049-1053.
89. Pan P.S., Vasko R.C., Lapera S.A., Johnson V.A., Sellers R.P., Lin C.C., Pan C.M., Davis M.R., Ardi V.C., McAlpine S.R. A comprehensive study of Sansalvamide A derivatives: the structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines. Bioorg. Med. Chem. 2009, 17:5806-5825.
90. Hambley T.W., Hawkins C.J., Lavin M.F., van den Brenk A., Watters D.J. Cycloxazoline: a cytotoxic cyclic hexapeptide from the ascidian Lissoclinum bistratum. Tetrahedron 1992, 48:341-348.
91. Watters D.J., Beamish H.J., Marshall K.A., Gardiner R.A., Seymour G.J., Lavin M.F. Accumulation of HL-60 leukemia cells in G2/M and inhibition of cytokinesis caused by two marine compounds, bistratene A and cycloxazoline. Cancer Chemother. Pharmacol. 1994, 33:399-409.
92. Carroll A.R., Feng Y., Bowden B.F., Coll J.C. Studies of Australian ascidians. 5. Virenamides A-C, new cytotoxic linear peptides from the colonial didemnid ascidian Diplosoma virens. J. Org. Chem. 1996, 61:4059-4061.
93. Taraboletti G., Poli M., Dossi R., Manenti L., Borsotti P., Faircloth G.T., Broggini M., D'Incalci M., Ribatti D., Giavazzi R. Antiangiogenic activity of aplidine, a new agent of marine origin. Br. J. Cancer 2004, 90:2418-2424.
94. Molina-Guijarro J.M., Macias A., Garcia C., Munoz E., Garcia-Fernandez L.F., David M., Nunez L., Martinez-Leal J.F., Moneo V., Cuevas C., Lillo M.P., Villalobos Jorge C., Valenzuela C., Galmarini C.M. Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. PLoS One 2011, 6:e19042.